Alterity Therapeutics (ASX:ATH) has announced that the Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in the United Kingdom.
"Our Phase 2 clinical trial continues to progress as planned with the launch of the study in the UK for patients with MSA," said CEO Dr David Stamler.
"In a short period of time we have now commenced enrolment in our second region, and we look forward to broadening our reach over the next several months. Because MSA is a rare disease, we are committed to providing access to the trial to eligible patients globally."
The Phase 2 clinical trial is a randomised, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
The company said the study will explore the effect of ATH434 treatment on neuroimaging and protein biomarkers, such as excess brain iron and aggregating α-synuclein, which are important contributors to MSA pathology.
